Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43
Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. COLL | 0.00 |
Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:
COLL) with a Neutral and lowers the price target from $45 to $43.
